In vivo targeting of diabetes-relevant human cell types with rAAV vectors
rAAV 载体体内靶向糖尿病相关人类细胞类型
基本信息
- 批准号:8812513
- 负责人:
- 金额:$ 360.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-30 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acinar CellAlkaline PhosphataseAlpha CellAntioxidantsAutoimmunityAutomobile DrivingBeta CellBiliaryBindingBinding SitesCDKN1C geneCapsidCellsClinicalCodeComplementary DNADNA Polymerase IIDNA ShufflingDiabetes MellitusDuct (organ) structureDuctal EpitheliumElementsEnhancersEpitheliumEvolutionGallbladderGene DeliveryGenerationsGenesGeneticGenetic TranscriptionGenomeGoalsHepatocyteHumanInsulin-Dependent Diabetes MellitusLibrariesLiverMethodsMicroRNAsModificationMutationNatural regenerationPancreasPancreatic delta CellPathway interactionsPatientsPropertyProteinsRNARNA SequencesReagentRecombinant adeno-associated virus (rAAV)Regulatory ElementSafetySpecificityStructure of beta Cell of isletUp-RegulationVariantViral VectorXenograft ModelXenograft procedureadeno-associated viral vectorcell typecellular transductionclinically relevantgene therapyin vivomutantneutralizing antibodynoveloval cellprogenitorpromoterpublic health relevancesmall hairpin RNAtherapeutic DNAtherapeutic targettranscription factortranscriptome sequencingvector
项目摘要
DESCRIPTION (provided by applicant): Clinical implementation of several of the most promising approaches to the treatment of type 1 diabetes will require the ability to perform genetic modifications of specific target cells in human patients in vivo. The pancreatic beta-cell is the most important target and therapeutic opportunities include the induction of regeneration, suppression of autoimmunity and upregulation of anti-oxidant pathways. Several other cell types have potential to be reprogrammed to functional beta-cells by directed fate conversion using transcription factors and microRNAs. This list includes pancreatic acinar cells, biliary duct epithelium of the liver, gall bladder epithelium, pancreatic delta-cells and alpha-cells. The goal f this application is to develop recombinant adeno-associated virus (rAAV) vectors capable of delivering genetic payloads to these target cells in humans efficiently and specifically. rAAV is already being used in several clinical gene therapy applications and has a good safety record. The required precision of gene delivery will be achieved by combining cell-type specific rAAV capsids with gene regulatory elements (promoters, enhancers and microRNA binding sites) that limit expression to only the target cell. rAAV capsid and the regulatory sequences will be optimized for each human cell type using xenograft models.
描述(由申请人提供):几种最有希望的1型糖尿病治疗方法的临床实施将需要在体内对人类患者的特定靶细胞进行基因修改的能力。胰腺β细胞是最重要的靶点和治疗机会,包括诱导再生、抑制自身免疫和上调抗氧化途径。其他几种类型的细胞也有可能通过使用转录因子和microRNAs进行定向命运转化而重新编程为具有功能的β细胞。该列表包括胰腺腺泡细胞、肝胆管上皮、胆囊腺上皮、胰腺三角洲细胞和α细胞。这项应用的目标是发展重组腺相关病毒(RAAV)载体,能够高效和特异地将基因有效载荷传递到人类的这些靶细胞。RAAV已经在几个临床基因治疗应用中使用,并有良好的安全性记录。通过将特定细胞类型的rAAV衣壳与基因调控元件(启动子、增强子和microRNA结合位点)相结合,可以实现所需的基因传递精度,这些元件将仅限于靶细胞表达。RAAV衣壳和调控序列将使用异种移植模型针对每种人类细胞类型进行优化。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Markus Grompe其他文献
Markus Grompe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Markus Grompe', 18)}}的其他基金
In vivo selection of gene modified hepatocytes
基因修饰肝细胞的体内选择
- 批准号:
10623157 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
In vivo selection of gene modified hepatocytes
基因修饰肝细胞的体内选择
- 批准号:
10378002 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
In vivo selection of gene modified hepatocytes
基因修饰肝细胞的体内选择
- 批准号:
10209238 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
相似海外基金
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10220574 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
Post-Transcriptional Processing of the Small Intestinal Alkaline Phosphatase in the Postnatal Developing Pig
产后发育猪小肠碱性磷酸酶的转录后加工
- 批准号:
RGPIN-2016-05827 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
Discovery Grants Program - Individual
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10413987 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
The role of tissue nonspecific alkaline phosphatase in brain endothelial cell homeostasis
组织非特异性碱性磷酸酶在脑内皮细胞稳态中的作用
- 批准号:
10601067 - 财政年份:2021
- 资助金额:
$ 360.47万 - 项目类别:
Selective targeting of human alkaline phosphatase isozymes
选择性靶向人碱性磷酸酶同工酶
- 批准号:
10359823 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Dietary induction of intestinal alkaline phosphatase intended to detoxify endotoxin and analysis of its mechanism of action.
膳食诱导肠道碱性磷酸酶解毒内毒素及其作用机制分析。
- 批准号:
20K05936 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Functional analysis of alkaline phosphatase, a stem cell marker, using human deciduous dental pulp cells derived from the patient with Hypophosphatasia (HPP)
使用源自低磷酸酯酶症 (HPP) 患者的人乳牙牙髓细胞对干细胞标记物碱性磷酸酶进行功能分析
- 批准号:
20K10210 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding the role of tissue non-specific alkaline phosphatase in osteogenesis for the therapy of hypophosphatasia.
了解组织非特异性碱性磷酸酶在成骨作用中的作用,以治疗低磷酸酯酶症。
- 批准号:
20K16894 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Selective targeting of human alkaline phosphatase isozymes
选择性靶向人碱性磷酸酶同工酶
- 批准号:
10117265 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Post-Transcriptional Processing of the Small Intestinal Alkaline Phosphatase in the Postnatal Developing Pig
产后发育猪小肠碱性磷酸酶的转录后加工
- 批准号:
RGPIN-2016-05827 - 财政年份:2020
- 资助金额:
$ 360.47万 - 项目类别:
Discovery Grants Program - Individual